ReviewPediatric nephrology (Berlin, Germany)2019
Uric acid and progression of chronic kidney disease.
Review in Pediatric nephrology (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05402397 (Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Effect of losartan on uric acid metabolism in children with proteinuric kidney disease: crossover randomized controlled clinical trial.Pediatric nephrology (Berlin, Germany) · 2025Trial
- Article
- Metabolic Endotypes for Dialysis Risk Stratification in Chronic Kidney Disease Stages G2-G4: A Pragmatic Cluster Analysis Using Routine Laboratory Tests.International journal of general medicine · 2026Article
- Development and Validation of a Predictive Model for Severe Tubular Atrophy/Interstitial Fibrosis in Patients with IgA Nephropathy: Multicenter Retrospective Study.JMIR medical informatics · 2025Article
- Identification of risk factors for renal progression in adults with IgAV: a retrospective cohort study of a single center in northwest China.International urology and nephrology · 2025Article
- The Urate-Lowering Effects and Renal Protective Activity of Iridoid Glycosides fromMolecules (Basel, Switzerland) · 2025Article
- Anti-Hyperuricemic and Nephroprotective Effects of Hydrolysate Derived from Silkworm Pupae (Nutrients · 2025Article
- Associations of low-carbohydrate diets patterns with the risk of hyperuricemia: a national representative cross-sectional study in Korea.Nutrition journal · 2025Article
- Advances in drug delivery systems for the management of gout and hyperuricemia.Frontiers in pharmacology · 2025Review
- Nonlinear association between triglyceride-glucose index and risk of hyperuricemia in early-stage cardiovascular-kidney-metabolic syndrome: a cross-sectional study of United States population.Frontiers in cardiovascular medicine · 2025Article
- Overview of pharmacodynamical research of traditional Chinese medicine on hyperuricemic nephropathy: from the perspective of dual-regulatory effect on the intestines and kidneys.Frontiers in pharmacology · 2025Review
- Article
- Role of hypertension in progression of pediatric CKD.Pediatric nephrology (Berlin, Germany) · 2023Review
- The association between serum uric acid and creatine phosphokinase in the general population: NHANES 2015-2018.BMC cardiovascular disorders · 2023Article
- Article
- Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2023Article
- An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2022Review
- The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia.Journal of healthcare engineering · 2022Article
- Effect Modification of Hyperuricemia, Cardiovascular Risk, and Age on Chronic Kidney Disease in China: A Cross-Sectional Study Based on the China Health and Nutrition Survey Cohort.Frontiers in cardiovascular medicine · 2022Article
- Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.International urology and nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between serum uric acid levels and human disease has garnered intense interest over the last decade including chronic kidney disease. Animal studies have provided evidence for a potential mechanistic role of uric acid in promoting progression of chronic kidney disease. Epidemiologic studies have also suggested an association between elevated serum uric acid levels and worsening renal function in the general population as well as in patients with chronic kidney disease. However, there is currently insufficient evidence to recommend the use of uric acid-lowering therapy to delay progression of chronic kidney disease in this patient population. Adequately powered, randomized, placebo-controlled trials are required to more precisely evaluate the risk and benefits of uric acid-lowering therapy in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.